VirusExpress® 293 AAV Production Platform Data Sheet

The VirusExpress® Platform offers a transfection-based solution to Adeno-Associated Viral (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to commercial production. VirusExpress® offers the flexibility to use either our contract manufacturing capabilities or your own facilities to speed your therapy to patients.

Our VirusExpress® Platform offers:

• A transfection-based solution to adeno-associated viral (AAV) upstream production challenges
• A suspension adapted cell line of 293 AAV Production Cells optimized for production of AAV vectors for gene therapy applications
• Chemically defined medium to alleviate animal origin and supply chain concerns
• Proven process performance at 3 L scale with genome titer exceeding 8 x 109 gc/mL
• Comprehensive user protocols to guide from seed train through at-scale transfection and virus production, allowing for seamless scale-up